Authors
Latest:
Treating AR-Indifferent Prostate CancerAhead of the ASCO-sponsored 2017 Genitourinary Cancers Symposium being held February 16th to February 18th in Orlando, Florida, we spoke with Dr. Ana Aparicio about the role of androgen receptors in prostate cancer.
Latest:
Molecular Characterizations of Diffuse Large B-Cell LymphomaWe spoke with Dr. Anas Younes about the molecular characteristics of diffuse large B-cell lymphoma.
Latest:
PTEN Mutation Status Potential Biomarker for Endometrial Cancer TherapiesLoss of function of the PTEN tumor suppressor gene leads to resistance to therapies targeting the Notch signaling pathway according to a mouse study presented at the 2016 Society of Gynecologic Oncology annual meeting, held in San Diego, March 19-22, 2016.
Latest:
The Re-emergence of Gemtuzumab Ozogamicin for AMLIn this interview with Jorge Cortes, MD, he discusses why gemtuzumab ozogamicin is experiencing a comeback for the treatment of patients with acute myeloid leukemia.
Latest:
IMDC Prognostic Category May Predict Treatment Course for Metastatic RCC PatientsA recent study published in European Urology suggests that patterns of treatment failure might help to predict what the next treatment should be for patients with metastatic renal cell carcinoma.
Latest:
Nivolumab Offers Durable Responses in Relapsed/Refractory Hodgkin LymphomaA follow-up analysis of the CheckMate-205 clinical trial found that nivolumab was associated with durable response rates in adults with relapsed or refractory Hodgkin lymphoma after ASCT.
Latest:
Pembrolizumab Yields Strong Long-Term Survival in Advanced MelanomaIn this video we discuss 3-year overall survival data from the KEYNOTE-001 trial, which studied the anti–PD-1 antibody pembrolizumab in patients with advanced melanoma.
Latest:
Woman With a Polypoid Endometrial TumorA 52-year-old woman presents with a polypoid endometrial tumor. What is your diagnosis?
Latest:
ASCO: Presentation Preview on Immunotherapy Approaches for Urological CancersAs part of our coverage of the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, we discuss some of the immunotherapy treatment options for urological cancers.
Latest:
Novel Quadruplet Therapy Shows Promise in Multiple MyelomaIn this interview with Charlotte Pawlyn, MB, BChir, PhD, she discusses results of the Myeloma XI study, which tested a novel quadruplet therapy for patients with newly diagnosed multiple myeloma.
Latest:
Genomic Guided Therapy: Show Me the Data!I was recently asked to speak to an audience of nonmedical adult participants enrolled in a leadership program in St. Petersburg, Florida. Many of the attendees were lawyers, bankers, and other professionals, who were generally foreign to the world of genetic cancer research. I was specifically asked to discuss how Moffitt Cancer Center is working to fight cancer through personalized medicine.
Latest:
'That’s Just My Luck to Get This Lousy Doctor'He came to our large, urban teaching hospital in search of a cure for his stomach cancer. We met during the workup stage of his care while he was suffering from intractable nausea, yet we still needed test results before we would know what kind of treatment we could offer.
Latest:
Uncovering Mechanisms Associated With ADT Resistance in Prostate CancerIn this video, David Goodrich, PhD, of Roswell Park Cancer Institute in Buffalo, discusses treatment resistance and disease relapse in prostate cancer.
Latest:
Why Elephants Don't Get CancerIn 1992, I moved to the Washington DC area and attended a conference on new and projected trends in cancer care at the National Institutes of Health.
Latest:
Incorporating Precision Medicine Into the Treatment of NSCLCDr. Kim discusses why non-small cell lung cancer should be considered the paradigm for precision medicine, and how treatment of the disease has changed over the last decade.
Latest:
P Values and 'Data Dredging' in Clinical ResearchWe spoke with Dr. Garrett-Mayer about concerns regarding statistical probability (P) values and “data dredging” in clinical research.
Latest:
The Role of Rucaparib in Ovarian CancerWe spoke with Dr. Elizabeth Swisher about the ARIEL2 trial and the role of rucaparib in ovarian cancer.
Latest:
New Biomarker May Help Detect Metastatic Endometrial CancerWe spoke with Dr. G. Larry Maxwell, Chair of the Department of Obstetrics and Gynecology at Inova Fairfax Hospital, about a potential new biomarker to help distinguish metastatic versus nonmetastatic disease in endometrial cancer.
Latest:
Applying Biologic Advances in Multiple Myeloma to Clinical PracticeIn this video, Gareth J. Morgan, MD, discusses the new biologic advances in multiple myeloma and how they are currently being applied to clinical practice.
Latest:
First Human Study Taking Place With Fatty Acid Synthase InhibitorWe spoke with Dr. Gerald Falchook about the first human study of a first-in-class molecule, fatty acid synthase inhibitor known as TVB-2640 for advanced solid tumors.
Latest:
Researchers Discuss MLL-Rearranged Acute Myeloid LeukemiasIn this interview, researchers discuss their analysis of a specific type of acute myeloid leukemia.
Latest:
The Role of Checkpoint Inhibitors in Advanced Lung CancerDr. Heather Wakelee discusses the management of lung cancer patients who have early or delayed progression while being treated with an immune checkpoint inhibitor.
Latest:
Lung Cancer Immunotherapy Updates From ASCOIn this podcast interview, Dr. Hossein Borghaei discusses some of the latest science presented at ASCO that focuses on immunotherapy in lung cancer.
Latest:
Immunotherapy Activity Shown in Multiple Myeloma TrialIn this interview, Dr. Ivan Borrello talks about a new approach to treating multiple myeloma at the American Society of Hematology Annual Meeting, held December 3–6, 2016.
Latest:
Potassium Channel Blockers Show Promise as Treatment for Brain TumorsHighly druggable ion channels, which are common therapeutic targets for heart disease and neurological conditions, may represent useful targets in cancer treatment as well, according to researchers from the University of California at San Francisco.
Latest:
Mutations May Help Identify Laryngeal Tumors with Favorable PrognosisResearchers have identified mutations that may help distinguish which laryngeal cancer patients could benefit from therapy, since the disease is notoriously resistant to chemotherapeutic treatments.
Latest:
PD-L1 As a Predictive Biomarker for Anti-PD-1/Anti-PD-L1 Therapies in Non-Small Cell Lung CancerImmunotherapies, such as anti-PD-1 and anti-PD-L1 antibodies, offer promising new treatment options for various malignancies including non-small cell lung cancer (NSCLC). With the advent of these immunotherapies, much interest and energy has been focused on developing a companion predictive biomarker.
Latest:
Pivotal PD-1 Treatment Helps Change Standard of Care in Lung Cancer“Having the opportunity to work within the industry in that sort of capacity, and then seeing a drug translate into clinical benefit in the clinic, was very exciting and gratifying.”
